Abstract | BACKGROUND: Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA ( PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent. METHODS:
Vaccine efficacy (VE) at 48 months was assessed against 6-month persistent infection (6MPI) with low-risk HPV types in the total vaccinated cohort (TVC) and in the TVC naive (for 25 HPV types tested) populations. RESULTS: In the TVC naive cohort, VE against 6MPI (95% confidence interval) was 34.5% (11.3 to 51.8) for HPV-6/11, 34.9% (9.1 to 53.7) for HPV-6, 30.3% (-45.0 to 67.5) for HPV-11, and 49.5% (21.0 to 68.3) for HPV-74. CONCLUSIONS: The HPV-16/18 AS04-adjuvanted vaccine appears to have moderate efficacy against persistent infections with a number of low-risk HPV types (HPV-6/11/74), which are responsible for the majority of external GWs, and recently, antibody and cell-mediated immune response to HPV-6/11 have been observed. These findings may help to explain the decrease in external GW diagnoses seen in England.
|
Authors | Anne Szarewski, S Rachel Skinner, Suzanne M Garland, Barbara Romanowski, Tino F Schwarz, Dan Apter, Song-Nan Chow, Jorma Paavonen, M Rowena Del Rosario-Raymundo, Julio C Teixeira, Newton S De Carvalho, Maria Castro-Sanchez, Xavier Castellsagué, Willy A J Poppe, Philippe De Sutter, Warner Huh, Archana Chatterjee, Wiebren A Tjalma, Ronald T Ackerman, Mark Martens, Kim A Papp, Jose Bajo-Arenas, Diane M Harper, Aureli Torné, Marie-Pierre David, Frank Struyf, Matti Lehtinen, Gary Dubin |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 208
Issue 9
Pg. 1391-6
(Nov 01 2013)
ISSN: 1537-6613 [Electronic] United States |
PMID | 24092907
(Publication Type: Journal Article)
|
Chemical References |
- ASO4 mixture
- Adjuvants, Immunologic
- Lipid A
- Papillomavirus Vaccines
- Aluminum Hydroxide
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Aluminum Hydroxide
(administration & dosage)
- Clinical Trials, Phase III as Topic
- Condylomata Acuminata
(epidemiology, immunology, prevention & control)
- Double-Blind Method
- Female
- Human papillomavirus 16
(immunology)
- Human papillomavirus 18
(immunology)
- Human papillomavirus 6
(immunology)
- Humans
- Incidence
- Incidental Findings
- Lipid A
(administration & dosage, analogs & derivatives)
- Multicenter Studies as Topic
- Papillomavirus Vaccines
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Vaccination
|